Severe Alopecia Areata
Dermatology
1
Pipeline Programs
1
Companies
3
Clinical Trials
2 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Small Molecule
1100%
+ 2 programs with unclassified modality
Competitive Landscape
1 companies ranked by most advanced pipeline stage
PfizerNEW YORK, NY
3 programs1
Ritlecitinib higher dosePhase 31 trial
LitfuloN/A1 trial
RitlecitinibN/ASmall Molecule1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2025
2026
2027
2028
2029
2030
PfizerRitlecitinib higher dose
PfizerLitfulo
PfizerRitlecitinib
Clinical Trials (3)
Total enrollment: 3,263 patients across 3 trials
A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.
Start: Sep 2025Est. completion: Jun 2030140 patients
Phase 3Recruiting
A Study to Learn About Litfulo Capsule in People With Severe Alopecia Areata in Routine Clinical Practice.
Start: Aug 2025Est. completion: Mar 20303,000 patients
N/ARecruiting
A Study to Learn About the Medicine Called Ritlecitinib in Adults With Severe Alopecia Areata in Real-world Settings
Start: Feb 2025Est. completion: May 2025123 patients
N/ACompleted
Related Jobs in Dermatology
MSL/Senior MSL, Dermatology - Tampa, Florida
AbbVie
Remote
6h ago
(Senior) Außendienstmitarbeiter Dermatology (all genders) - Region Thüringen
AbbVie
Remote
6h ago
(Senior) Außendienstmitarbeiter Dermatology (all genders) - Region Thüringen
AbbVie
Remote
6h ago
Regional Sales Trainer - Dermatology (Central / West Regions)
AbbVie
Remote
7h ago
Regional Sales Trainer - Dermatology (Northeast / Southeast Regions)
AbbVie
Remote
7h ago
Delegado Especialista Ventas Dermatología (Inmunología)
AbbVie
Remote
11h ago
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs — potential near-term approvals
2 actively recruiting trials targeting 3,263 patients
1 companies competing in this space